Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Will the present Covid-19 vaccines protect you against the Omicron variant of the virus that has created a global scare?
Well, scientists are studying the virus, but vaccine makers are already at work to adapt their shots to the virus that's considered to be highly infectious.
Pfizer, alongwith its partners BioNTech, plans to ship the new version of their shot within 100 days, Bloomberg has reported.
US-based vaccine maker Moderna expects a similar time-frame for a new vaccine tailored for 'Omicron'. It will possibly be available by early next year, Moderna's chief medical officer Paul Burton has told BBC.
Scientists, however, say they need more time to study the virus to come to any conclusion. There is still little clarity on its infectious nature, the severity of the disease it causes, and how well vaccines protect against it.
The World Health Organization said the overall risk from Omicron was "very high" and warned that any major surge would put pressure on health systems and cause more deaths.

Will we need new vaccines for Omicron? Here's what vaccine makers say

Omicron scare: Scientists are still studying the virus, but vaccine makers are already at work to adapt their shots to the new Covid variant

Vaccine makers are working to adapt their shots to Omicron

Will the present Covid-19 vaccines protect you against the Omicron variant of the virus that has created a global scare?
Well, scientists are studying the virus, but vaccine makers are already at work to adapt their shots to the virus that's considered to be highly infectious.
Pfizer, alongwith its partners BioNTech, plans to ship the new version of their shot within 100 days, Bloomberg has reported.
US-based vaccine maker Moderna expects a similar time-frame for a new vaccine tailored for 'Omicron'. It will possibly be available by early next year, Moderna's chief medical officer Paul Burton has told BBC.
Scientists, however, say they need more time to study the virus to come to any conclusion. There is still little clarity on its infectious nature, the severity of the disease it causes, and how well vaccines protect against it.
&nbsp;
&nbsp;
&nbsp;
&nbsp;

Omicron scare: Scientists are still studying the virus, but vaccine makers are already at work to adapt their shots to the new variant

Will the present Covid-19 vaccines protect you against the Omicron variant of the virus that has created a global scare?
Well, scientists are studying the virus, but vaccine makers are already at work to adapt their shots to the virus that's considered to be highly infectious.
Pfizer, alongwith its partners BioNTech, plans to ship the new version of their shot within 100 days, Bloomberg has reported.
US-based vaccine maker Moderna expects a similar time-frame for a new vaccine tailored for 'Omicron'. It will possibly be available by early next year, Moderna's chief medical officer Paul Burton has told BBC.
Scientists, however, say they need more time to study the virus to come to any conclusion. There is still little clarity on its infectious nature, the severity of the disease it causes, and how well vaccines protect against it.
The World Health Organization said the overall risk from Omicron was "very high" and warned that any major surge would put pressure on health systems and cause more deaths.
Also Watch:&nbsp;<a href="https://www.editorji.com/coronavirus/symptoms-unfamiliar-but-mild-doctor-who-detected-omicron-variant-1638207153909" target="_blank">Symptoms unfamiliar but mild: doctor who detected Omicron variant</a>

People fully vaccinated with the Pfizer-BioNTech vaccine are likely to have more than five times lower levels of neutralising antibodies against the Delta variant compared to the original strain, according to research published in The Lancet journal.The Delta strain was first identified in India.
The study also shows that levels of these antibodies that are able to recognise and fight the virus are lower with increasing age, and that levels decline over time, providing additional evidence in support of plans to deliver a booster dose to vulnerable people.

Pfizer jab produces less antibodies against Delta variant of coronavirus: Lancet study

People fully vaccinated with the Pfizer-BioNTech vaccine are likely to have more than five times lower levels of neutralising antibodies against the Delta variant compared to the original strain, according to research published in The Lancet journal. The Delta strain was first identified in India.
The study also shows that levels of these antibodies that are able to recognise and fight the virus are lower with increasing age, and that levels decline over time, providing additional evidence in support of plans to deliver a booster dose to vulnerable people.

Pfizer jab produces less antibodies against Delta variant: Lancet study

Pfizer jab produces&nbsp;less antibodies against Delta variant: Lancet Lancet: Pfizer vaccine recipients have 5 time lower antibodies&nbsp;against Delta variant Top study: levels of antibodies fall with rising age and over time

People fully vaccinated with the Pfizer-BioNTech vaccine are likely to have more than five times lower levels of neutralising antibodies against the Delta variant compared to the original strain, according to research published in The Lancet journal. The Delta strain was first identified in India.
The study also shows that levels of these antibodies that are able to recognise and fight the virus are lower with increasing age, and that levels decline over time, providing additional evidence in support of plans to deliver a booster dose to vulnerable people.

Any vaccine maker, including Pfizer that has sought emergency-use authorisation for its Covid-19 shot in India, must conduct an additional local study to be considered for govt approval, news agency Reuters has reported quoting a senior government official. In December, Pfizer had sought govt approval to import and distribute its vaccine in India without doing local trials. Serum Institute of India, which is manufacturing the Oxford vaccine, did a months long local study on more than 1,500 people before seeking and receiving emergency approval on January 3.

India tells Pfizer to do local study before approval: report

The Indian govt wants Pfizer to do a local study on its Covid&nbsp;vaccine before seeking approval, says report

Any vaccine maker, including Pfizer that has sought emergency-use authorisation for its Covid-19 shot in India, must conduct an additional local study to be considered for govt approval, news agency Reuters has reported quoting a senior government official. In December, Pfizer had sought govt approval to import and distribute its vaccine in India without doing local trials. Serum Institute of India, which is manufacturing the Oxford vaccine, did a months long local study on more than 1,500 people before seeking and receiving emergency approval on January 3.

AstraZeneca's Covid-19 vaccine enters phase 3, Trump hopeful 

Ahead of the November Presidential election, President Trump announced the vaccine developed by AstraZeneca has reached phase three of clinical trials

AstraZeneca&nbsp;Covid-19 vaccine enters phase 3 trial Polls in Nov: Trump hopeful for an early vaccine Vaccine candidate to be tried on 80,000 US adults

Ahead of the November Presidential election, President Trump announced the vaccine developed by AstraZeneca has reached phase three of clinical trials. Trump expressed for a hopeful approval soon and told the reporters that no one thought US&nbsp;would be able to develop the vaccine so soon, which otherwise can take years to develop. The vaccine&nbsp;candidate would be tried on 30,000 US nationals across 80 cities.&nbsp;AstraZeneca is one of the leaders to develop Covid-19 vaccine in the United States amongst Moderna and Pfizer Inc.

pfizer inc.

Categories